Preliminary evaluation of cell-based carriers of novel conjugated polymer nanoparticles with antitumoral action

BEAUGE L.; PALACIOS R.E.; IBARRA L.E.

Santa Fe

Simposio; IX Simposio Latinoamericano de Tecnología de Cultivos Celulares; 2022

Facultad de Bioquimica y Ciencias Biologicas - UNL

In recent years, the use of cells to transport drugs has gained importance as a way to increasethe arrival and accumulation at necessary sites, such as solid tumors [1]. Conjugated polymernanoparticles (CPNs) are an example of cargos to be transported by cells, due to the intrinsicability to emit fluorescence and generate cytotoxic damage after application of external stimulisuch as light [2]. We have previously demonstrated the ability of immune cells to transport akind of CPNs-F8BT to brain tumors [3]. At the present, we are looking to develop new CPNsand evaluate them as cargo for cell-based delivery.Two types of CPNs were synthetized using CPs: PCPDTBT ((Poly[2,6-(4,4-bis-(2-ethylhexyl)-4H-cyclopenta[2,1-b; 3,4-b´]dithiophene)-alt-4,7(2, 1, 3-benzothiadiazole)]) and PFOTBT (Poly[2,7-(9,9-di-octyl-fluorene)-alt-4,7-bis(thiophen-2-yl)benzo-2,1,3-t hyadiazole). The method usedwas nanoprecipitation and the resulting CPNs were characterized by UV-Visible absorption,fluorescence emission spectroscopy and dynamic light scattering (DLS). The biologicalevaluation of cell incorporation and biocompatibility was done with monocytes from humancell lines THP-1 and U937.The incorporation of CPNs into cells could be successfully determined using flow cytometryand Odyssey® CLx Infrared Imaging System. Both CPNs showed excellent fluorescentbrightness for bioimaging, were not toxic at the concentrations evaluated and were taken upsuccessfully by monocytes. CPNs synthesized with the chosen CPs would be ideal candidatesfor cell labelling and trafficking evaluation in preclinical animal models.